Dashboard
Manage Tickers

NVSNOVARTIS AG

NYSE novartis.com


$ 99.06 $ 1.34 (1.37 %)    

Tuesday, 07-May-2024 15:59:58 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 440.32 $ 0.07 (0.02 %)
DIA $ 388.70 $ 0.29 (0.07 %)
SPY $ 517.26 $ 0.57 (0.11 %)
TLT $ 90.79 $ 0.55 (0.61 %)
GLD $ 214.23 $ -0.99 (-0.46 %)
$ 99.07
$ 98.56
$ 99.06 x 200
$ 99.16 x 200
$ 98.56 - $ 99.18
$ 88.80 - $ 104.78
1,158,976
na
202.5B
$ 0.56
$ 13.64
TBD
na
na ($ 0.04)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

federal-trade-commission-targets-junk-patent-listings-for-diabetes-weight-loss-asthma-drugs-from-companies-like-novo-nordisk-astrazeneca
Federal Trade Commission Targets 'Junk Pat...
05/01/2024 20:11:33

The FTC intensifies efforts against pharmaceutical patent listings, disputing junk patents for diabetes, weight loss, asthma, a...

peptidream-announces-expansion-of-peptide-discovery-collaboration-with-novartis-peptidream-will-receive-an-upfront-payment-of-180m-and-is-eligible-to-receive-up-to-271b-in-milestone-payments
PeptiDream Announces Expansion Of Peptide ...
04/30/2024 11:18:34

morphosys-says-novartis-deal-progressing-steadily-despite-safety-concerns-over-bone-marrow-cancer-drug-pelabresib
MorphoSys Says Novartis Deal Progressing S...
04/29/2024 16:36:10

MorphoSys faces safety concerns over pelabresib, a myelofibrosis treatment. Physicians report patients transitioning rapidly to...

will-earnings-cheer-continue-to-buoy-markets-apple-amazon-pfizer-coinbase-lead-flurry-of-q1-reports-this-week
Will Earnings Cheer Continue To Buoy Marke...
04/29/2024 05:51:21

With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and...

whats-going-on-with-pfizer-stock-on-thursday
What's Going On With Pfizer Stock On Thurs...
04/25/2024 17:51:32

GSK initiates legal proceedings against Pfizer and BioNTech over alleged COVID-19 vaccine patent infringement, intensifying hig...

novartis-pharms-corp-gets-fda-new-drug-application-approval-for-vijoice
Novartis Pharms Corp Gets FDA New Drug App...
04/25/2024 15:09:30

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218466

bmo-capital-maintains-market-perform-on-novartis-raises-price-target-to-116
BMO Capital Maintains Market Perform on No...
04/24/2024 15:03:14

BMO Capital analyst Etzer Darout maintains Novartis (NYSE:NVS) with a Market Perform and raises the price target from $114 t...

novartis-and-medicines-for-malaria-venture-announced-data-from-phase-23-calina-study-demonstrating-that-formulated-coartem-developed-for-babies-weighing-less-than-5kg-with-malaria-has-the-required-pharmacokinetic-profile-good-efficacy-and-safety
Novartis And Medicines For Malaria Venture...
04/24/2024 09:37:35

https://www.novartis.com/news/media-releases/novartis-and-medicines-malaria-venture-announce-positive-efficacy-and-safety-data-...

fda-approves-novartis-lutathera-as-first-therapy-for-pediatric-patients-with-gastroenteropancreatic-neuroendocrine-tumors
FDA Approves Novartis' Lutathera As First ...
04/23/2024 19:05:30

Discover Novartis' FDA approval for Lutathera in pediatric patients with GEP-NETs, marking a pivotal milestone in treating ...

novartis-radioligand-therapy-lutathera-fda-approved-first-medicine-specifically-for-pediatric-patients-with-gastroenteropancreatic-neuroendocrine-tumors
Novartis Radioligand Therapy Lutathera FDA...
04/23/2024 18:15:30

https://www.novartis.com/news/media-releases/novartis-radioligand-therapy-lutathera-fda-approved-first-medicine-specifically-pe...

stocks-rally-on-weaker-pmi-data-tech-earnings-optimism-dollar-falls-whats-driving-markets-tuesday
Stocks Rally On Weaker PMI Data, Tech Earn...
04/23/2024 17:33:38

Stocks surged as weak economic data raised hopes for Fed rate cut. S&P 500 up 1.2%, Nasdaq 100 up 1.5%, Dow Jones up 0.6%. ...

novartis-stock-gains-on-european-drugmakers-q1-earnings-surprise-lifts-annual-outlook
Novartis Stock Gains On European Drugmaker...
04/23/2024 12:25:42

Discover Novartis' Q1 EPS soars 17% to $1.80, surpassing estimates. Sales hit $11.83B, up 10%. Entresto sales surge 36%, Co...

wall-street-set-to-open-higher-as-tesla-kicks-off-magnificent-7-earnings-why-this-analyst-thinks-market-weakness-is-a-healthy-pullback
Wall Street Set To Open Higher As Tesla Ki...
04/23/2024 10:55:31

The mood on Wall Street turned tentative on Tuesday as investors awaited earnings reports from the “Magnificent 7,” companies t...

novartis-now-expects-2024-net-sales-to-grow-high-single-to-low-double-digit-prior-mid-single-digit-and-core-operating-income-to-grow-low-double-digit-to-mid-teens-prior-high-single-digit
Novartis Now Expects 2024 Net Sales To Gro...
04/23/2024 06:37:04

novartis-q1-2024-adj-eps-180-beats-167-estimate-sales-11829b-beat-11433b-estimate
Novartis Q1 2024 Adj EPS $1.80 Beats $1.67...
04/23/2024 06:28:20

Novartis (NYSE:NVS) reported quarterly earnings of $1.80 per share which beat the analyst consensus estimate of $1.67 by 7.78 p...

can-magnificent-7-help-script-market-turnaround-earnings-pick-up-pace-with-microsoft-meta-alphabet-and-tesla-expected-this-week
Can Magnificent 7 Help Script Market Turna...
04/21/2024 21:45:15

Corporate profit growth rose in Q3 2023 and is expected to continue in Q1.

fda-mandates-boxed-warning-for-bristol-myers-johnson--johnson-car-t-based-blood-cancer-therapies
FDA Mandates "Boxed Warning" For Bristol M...
04/19/2024 13:28:52

Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings—t...

novartis-multiple-sclerosis-drug-kesimpta-shows-substantial-benefit-of-up-to-6-years
Novartis Multiple Sclerosis Drug Kesimpta ...
04/17/2024 15:48:58

Sustained efficacy with Novartis' Kesimpta for up to 6 years in recently diagnosed relapsing multiple sclerosis. Significan...

novartis-announced-earlier-continuous-kesimpta-treatment-for-up-to-six-years-showed-sustained-efficacy-in-recently-diagnosed-3-years-treatment-nave-people-living-with-relapsing-multiple-sclerosis--in-analysis-of-alithios-open-label-extension-study
Novartis Announced Earlier, Continuous Kes...
04/17/2024 09:28:08

Continuous Kesimpta® treatment for up to six years showed sustained efficacy in recently diagnosed (≤3 years) treatment-naïve...

avalo-therapeutics-newly-acquired-ex-eli-lilly-drug-could-stand-out-in-competitive-hidradenitis-suppurativa-market-analyst-upgrades
Avalo Therapeutics' Newly Acquired Ex-Eli ...
04/16/2024 18:25:00

Unlock the potential of Avalo Therapeutics with AVTX-009, a promising drug for hidradenitis suppurativa. Oppenheimer upgrades t...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION